Search research articles
Contact Us
Filters
Showing results (171-180 of 217) with videos related to
Page
of 22
Sort By:
JCO Precision Oncology
|
January 14, 2026
Early Clinical and Molecular Biomarkers in Patients With Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: CHIVA Phase II GINECO Trial
Félix Blanc-Durand, Benoit You, Yahia Adnani, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes
Lucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 9, 2021
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3
Andrew R Clamp, Domenica Lorusso, Amit M Oza, et al.
NPJ Precision Oncology
|
May 30, 2026
Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer
Doris Kim, Heekyung Chung, Mona Abed, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2020
Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy
Alicia León-Castillo, Stephanie M de Boer, Melanie E Powell, et al.
Journal for Immunotherapy of Cancer
|
August 6, 2024
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
Michael Schenker, Mauricio Burotto, Martin Richardet, et al.
Nature Communications
|
March 17, 2022
Tertiary lymphoid structures critical for prognosis in endometrial cancer patients
Nanda Horeweg, Hagma H Workel, Dominik Loiero, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
January 8, 2024
Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter Hypermethylation
Merve Kaya, Cathalijne C B Post, Carli M Tops, et al.
The Lancet. Oncology
|
May 4, 2020
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial
Jonathan A Ledermann, Amit M Oza, Domenica Lorusso, et al.
Cancer Medicine
|
September 22, 2021
Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety
Ana Oaknin, Amit M Oza, Domenica Lorusso, et al.
Page
of 22
Search research articles
Search
Showing results (171-180 of 217) with videos related to
Sort By:
Page
of 22
JCO Precision Oncology
|
January 14, 2026
Early Clinical and Molecular Biomarkers in Patients With Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: CHIVA Phase II GINECO Trial
Félix Blanc-Durand, Benoit You, Yahia Adnani, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes
Lucy Haggstrom, Yeh Chen Lee, Clare Scott, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 9, 2021
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3
Andrew R Clamp, Domenica Lorusso, Amit M Oza, et al.
NPJ Precision Oncology
|
May 30, 2026
Cyclin E1 overexpression identifies a therapeutically relevant poor prognostic patient subgroup in high-grade serous ovarian cancer
Doris Kim, Heekyung Chung, Mona Abed, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2020
Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy
Alicia León-Castillo, Stephanie M de Boer, Melanie E Powell, et al.
Journal for Immunotherapy of Cancer
|
August 6, 2024
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
Michael Schenker, Mauricio Burotto, Martin Richardet, et al.
Nature Communications
|
March 17, 2022
Tertiary lymphoid structures critical for prognosis in endometrial cancer patients
Nanda Horeweg, Hagma H Workel, Dominik Loiero, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
January 8, 2024
Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter Hypermethylation
Merve Kaya, Cathalijne C B Post, Carli M Tops, et al.
The Lancet. Oncology
|
May 4, 2020
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial
Jonathan A Ledermann, Amit M Oza, Domenica Lorusso, et al.
Cancer Medicine
|
September 22, 2021
Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety
Ana Oaknin, Amit M Oza, Domenica Lorusso, et al.
Page
of 22